Form 4: Fulcrum Therapeutics Director Colin Hill Granted 36,000 Stock Options

Fulcrum Therapeutics, Inc. director Colin Hill was granted 36,000 stock options with an exercise price of $7.38 per share, vesting over one year.

Summary

• Colin Hill, a Director of Fulcrum Therapeutics, Inc. (FULC), was granted 36,000 stock options.
• The options have an exercise price of $7.38 per share.
• The grant date for these options was June 26, 2025.
• The options are scheduled to expire on June 25, 2035.
• The options will vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Sentiment

Score: 7

Explanation: The document reports a standard, positive event of a director receiving equity compensation, which aligns interests and is generally viewed favorably as a sign of commitment, with no negative implications disclosed.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Risks

• The value of the stock options is dependent on the future performance of Fulcrum Therapeutics' stock price; if the stock price does not exceed the exercise price of $7.38, the options may not be profitable.
• Vesting of the options is subject to Colin Hill's continued service as a director.

Future Outlook

The stock options are scheduled to vest fully on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on continued service.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership incentives with long-term shareholder value creation. This type of equity compensation is particularly prevalent in growth-oriented sectors like biotech, where future potential is a significant driver of valuation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across publicly traded companies, particularly in the life sciences sector, to attract and retain qualified board members.
• The vesting schedule, typically one year for director grants, is common, ensuring continued commitment.
• The exercise price being set at the market price on the grant date is standard for incentive stock options.

Related Party Transactions

• The grant of stock options to Colin Hill, a director of Fulcrum Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options' value increases with the company's stock price.
• Employees: While not directly impacting employees, director compensation practices can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 26, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Colin Hill's continued service.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Stock Options, SEC Form 4, Director Compensation, Equity Grant, Insider Transaction, Corporate Governance